Efficacy and Safety of Rivaroxaban in Patients with Peripheral Artery Disease: A GRADE-assessed Systematic Review and Meta-Analysis.

Ann Vasc SurgJul 14, 2026 (epub)
Clinical ResearchCardiologyVascular Surgery

Muhammad Shahzaib, Muhammad Roshaan, Muhammad Khan Buhadur Ali et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis evaluated the efficacy and safety of rivaroxaban in 39,991 patients with peripheral artery disease (PAD). Rivaroxaban significantly reduced composite efficacy outcomes (RR = 0.84), acute limb ischemia (RR = 0.65), and thromboembolism (RR = 0.60), but was associated with a higher risk of major bleeding (HR = 1.54).

Key findings

  • Rivaroxaban reduced composite efficacy outcomes compared to control (RR = 0.84, P < 0.001).
  • Significant reduction in acute limb ischemia with rivaroxaban (RR = 0.65, P < 0.001).
  • Rivaroxaban alone significantly reduced amputation risk (RR = 0.50, P = 0.003).
  • Increased risk of major bleeding associated with rivaroxaban (HR = 1.54, P < 0.001).

Why it matters

The findings highlight the potential benefits of rivaroxaban in reducing ischemic events in PAD patients, while also emphasizing the need to consider the increased bleeding risk when making treatment decisions.

Source

PubMed · PMID 42448029

Published in Ann Vasc Surg. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Cardiology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.